BNP Paribas Financial Markets
DSGN icon

BNP Paribas Financial Markets’s Design Therapeutics DSGN Stock Holding History

BNP Paribas Financial Markets’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.2K Sell
5,751
-44,521
-89% -$555K ﹤0.01% 4657
2026
Q1 		$535K Sell
50,272
-44,556
-47% -$451K ﹤0.01% 3547
2025
Q4 		$889K Buy
94,828
+89,695
+1,747% +$702K ﹤0.01% 3196
2025
Q3 		$38.7K Buy
5,133
+1,310
+34% +$6.56K ﹤0.01% 4701
2025
Q2 		$12.9K Sell
3,823
-49,049
-93% -$184K ﹤0.01% 4777
2025
Q1 		$204K Buy
52,872
+12,583
+31% +$60K ﹤0.01% 3680
2024
Q4 		$249K Buy
+40,289
New +$233K ﹤0.01% 3739

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Financial Markets's DSGN Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Design Therapeutics (DSGN) stake by 89% in Q2 2026, selling an estimated $555K and leaving 5,751 shares worth $83.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4657.

BNP Paribas Financial Markets first reported a position in DSGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $889K in Q4 2025. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • BNP Paribas Financial Markets held 5,751 shares of Design Therapeutics worth $83.2K as of Q2 2026.
  • BNP Paribas Financial Markets sold 44,521 Design Therapeutics shares in Q2 2026, an estimated $555K.
  • Design Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4657 holding.
  • BNP Paribas Financial Markets first reported a position in Design Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Design Therapeutics position peaked at $889K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.